Welcome to our dedicated page for Horizon Space Acquisition II SEC filings (Ticker: HSPTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Horizon Space Acquisition II's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Horizon Space Acquisition II's regulatory disclosures and financial reporting.
Horizon Space Acquisition II Sponsor Corp. and Mingyu Li have filed Amendment No. 1 to their Schedule 13D to report that they no longer own any shares of Horizon Space Acquisition II Corp. (HSPT). The cover pages show 0 shares beneficially owned and 0% of the ordinary share class.
The change follows the June 12, 2026 business combination in which HSPT and SL Bio Ltd. became subsidiaries of SL Science Holding Limited (PubCo). In that transaction, each HSPT ordinary share was cancelled and exchanged for one PubCo ordinary share, and the sponsor ceased to hold any HSPT securities. This amendment is characterized as a final, "exit" filing for the reporting persons.
Horizon Space Acquisition II Sponsor Corp. and Mingyu Li have filed Amendment No. 1 to their Schedule 13D to report that they no longer own any shares of Horizon Space Acquisition II Corp. (HSPT). The cover pages show 0 shares beneficially owned and 0% of the ordinary share class.
The change follows the June 12, 2026 business combination in which HSPT and SL Bio Ltd. became subsidiaries of SL Science Holding Limited (PubCo). In that transaction, each HSPT ordinary share was cancelled and exchanged for one PubCo ordinary share, and the sponsor ceased to hold any HSPT securities. This amendment is characterized as a final, "exit" filing for the reporting persons.
Horizon Space Acquisition II Corp. director and Chief Executive Officer Li Mingyu filed a Form 4 as a ten percent owner, but the filing reports no insider transactions. All buy, sell, acquire, dispose, and derivative transaction counts are zero, indicating no changes in reported holdings in this period.
Horizon Space Acquisition II Corp. director and Chief Executive Officer Li Mingyu filed a Form 4 as a ten percent owner, but the filing reports no insider transactions. All buy, sell, acquire, dispose, and derivative transaction counts are zero, indicating no changes in reported holdings in this period.
Horizon Space Acquisition II Corp. director Cai Tianchen filed a Form 4 that reports no equity transactions for the period covered. The filing shows no open-market purchases or sales, no derivative exercises, and no gifts or restructurings, indicating Cai’s reported holdings did not change in this timeframe.
Horizon Space Acquisition II Corp. director Cai Tianchen filed a Form 4 that reports no equity transactions for the period covered. The filing shows no open-market purchases or sales, no derivative exercises, and no gifts or restructurings, indicating Cai’s reported holdings did not change in this timeframe.
Horizon Space Acquisition II Corp. filed a Form 4 listing Chief Financial Officer Zhai Min as a reporting person. The provided data show no reportable insider purchases, sales, option exercises, or other equity transactions, and no holdings or derivative positions are detailed in this excerpt.
Horizon Space Acquisition II Corp. filed a Form 4 listing Chief Financial Officer Zhai Min as a reporting person. The provided data show no reportable insider purchases, sales, option exercises, or other equity transactions, and no holdings or derivative positions are detailed in this excerpt.
Horizon Space Acquisition II Corp. director Xu Qian filed a Form 4 reporting no insider trading activity. The filing shows no common stock or derivative transactions, no shares bought or sold, and no option exercises, gifts, tax withholdings, or restructurings during the reported period.
Horizon Space Acquisition II Corp. director Xu Qian filed a Form 4 reporting no insider trading activity. The filing shows no common stock or derivative transactions, no shares bought or sold, and no option exercises, gifts, tax withholdings, or restructurings during the reported period.
Horizon Space Acquisition II Corp. filed a Form 25 notifying the Nasdaq Stock Market LLC of the removal of its Ordinary Shares, Rights and Units from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The filing states both the Exchange and the issuer complied with the rules governing withdrawal.
Horizon Space Acquisition II Corp. filed a Form 25 notifying the Nasdaq Stock Market LLC of the removal of its Ordinary Shares, Rights and Units from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The filing states both the Exchange and the issuer complied with the rules governing withdrawal.
Horizon Space Acquisition II Corp. reported a small net loss of $29,122 for the quarter ended March 31, 2026, as interest income of $588,076 on its Trust investments was more than offset by formation and operating costs of $364,905 and interest expense of $252,293.
The SPAC redeemed 3,219,311 ordinary shares for $34,221,276, reducing the Trust Account to $39,390,860 and leaving a working capital deficit of $1,784,554. It continues to pursue the SL Bio business combination, supported by a $7,800,000 PIPE and multiple extension deposits, but management discloses substantial doubt about the company’s ability to continue as a going concern if a deal is not completed by the current deadline.
Horizon Space Acquisition II Corp. reported a small net loss of $29,122 for the quarter ended March 31, 2026, as interest income of $588,076 on its Trust investments was more than offset by formation and operating costs of $364,905 and interest expense of $252,293.
The SPAC redeemed 3,219,311 ordinary shares for $34,221,276, reducing the Trust Account to $39,390,860 and leaving a working capital deficit of $1,784,554. It continues to pursue the SL Bio business combination, supported by a $7,800,000 PIPE and multiple extension deposits, but management discloses substantial doubt about the company’s ability to continue as a going concern if a deal is not completed by the current deadline.
Horizon Space Acquisition II Corp. notified the SEC it will file its quarterly report on Form 10-Q late for the period ended March 31, 2026 under Rule 12b-25. The company expects a significant change in its results for the quarter due to extension-fee deposits totaling $790,000 and a shareholder redemption payment of $34,221,276 related to 3,219,311 ordinary shares redeemed on March 17, 2026. The registrant states it intends to file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
Horizon Space Acquisition II Corp. notified the SEC it will file its quarterly report on Form 10-Q late for the period ended March 31, 2026 under Rule 12b-25. The company expects a significant change in its results for the quarter due to extension-fee deposits totaling $790,000 and a shareholder redemption payment of $34,221,276 related to 3,219,311 ordinary shares redeemed on March 17, 2026. The registrant states it intends to file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
Horizon Space Acquisition II Corp. received an amended Schedule 13G/A filing by Mizuho Financial Group, Inc. stating that Mizuho (through its subsidiaries) reports 0 shares beneficially owned of Horizon Space Acquisition II Corp. common stock (CUSIP G4627B103), representing 0.0% of the class. The filing identifies Mizuho Securities USA LLC as the subsidiary holding any underlying position and includes the parent certification regarding comparable foreign regulatory scheme. The signature on the amendment is dated 05/14/2026.
Horizon Space Acquisition II Corp. received an amended Schedule 13G/A filing by Mizuho Financial Group, Inc. stating that Mizuho (through its subsidiaries) reports 0 shares beneficially owned of Horizon Space Acquisition II Corp. common stock (CUSIP G4627B103), representing 0.0% of the class. The filing identifies Mizuho Securities USA LLC as the subsidiary holding any underlying position and includes the parent certification regarding comparable foreign regulatory scheme. The signature on the amendment is dated 05/14/2026.
Horizon Space Acquisition II Corp. extended the deadline to complete its initial business combination by one month, from April 18, 2026 to May 18, 2026. This is the third of up to twelve one‑month extensions allowed under its charter amendment.
The sponsor deposited a $50,000 extension fee into the company’s trust account and received an unsecured promissory note for the same amount. The note bears no interest and is due at the business combination or the company’s expiry, and may be converted into private units at $10.00 per unit.
Horizon Space Acquisition II Corp. extended the deadline to complete its initial business combination by one month, from April 18, 2026 to May 18, 2026. This is the third of up to twelve one‑month extensions allowed under its charter amendment.
The sponsor deposited a $50,000 extension fee into the company’s trust account and received an unsecured promissory note for the same amount. The note bears no interest and is due at the business combination or the company’s expiry, and may be converted into private units at $10.00 per unit.